AVTX

Avalo Therapeutics (AVTX)

Avalo Therapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:AVTX

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/14	01 : 38	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:AVTX	Avalo Therapeutics Inc
2024/05/13	20 : 33	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:AVTX	Avalo Therapeutics Inc
2024/05/13	20 : 30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AVTX	Avalo Therapeutics Inc
2024/05/13	20 : 30	GlobeNewswire Inc.	Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates	NASDAQ:AVTX	Avalo Therapeutics Inc
2024/04/02	20 : 00	GlobeNewswire Inc.	Avalo Therapeutics Appoints Biotech Leaders to Board of Directors	NASDAQ:AVTX	Avalo Therapeutics Inc
2024/03/30	05 : 01	GlobeNewswire Inc.	Avalo Reports 2023 Financial Results and Provides Business Updates	NASDAQ:AVTX	Avalo Therapeutics Inc
2024/03/28	05 : 01	GlobeNewswire Inc.	Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million	NASDAQ:AVTX	Avalo Therapeutics Inc
2024/02/15	11 : 13	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:AVTX	Avalo Therapeutics Inc
2024/02/15	00 : 02	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:AVTX	Avalo Therapeutics Inc
2024/02/01	06 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/12/29	07 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/12/27	21 : 00	GlobeNewswire Inc.	Avalo Therapeutics Announces 1-for-240 Reverse Stock Split	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/12/22	06 : 05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/12/22	06 : 01	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/12/21	06 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/12/07	21 : 02	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/12/07	21 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/12/07	21 : 00	GlobeNewswire Inc.	Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/11/16	21 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/11/09	21 : 21	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/11/09	21 : 04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/11/09	21 : 00	GlobeNewswire Inc.	Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/10/31	20 : 21	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/10/31	20 : 00	GlobeNewswire Inc.	Avalo Completes Divestiture of AVTX-800 Series	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/10/20	05 : 15	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/10/20	05 : 06	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/10/20	05 : 01	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/10/18	05 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/10/06	05 : 02	Edgar (US Regulatory)	Form PRE 14A - Other preliminary proxy statements	NASDAQ:AVTX	Avalo Therapeutics Inc
2023/09/26	20 : 04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:AVTX	Avalo Therapeutics Inc